BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:BLC - FR0000035370 - Common Stock
25.2 EUR
+0.1 (+0.4%)
Taking everything into account, BLC scores 4 out of 10 in our fundamental rating. BLC was compared to 32 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of BLC while its profitability can be described as average. BLC is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- BLC had positive earnings in the past year.
- In the past year BLC had a positive cash flow from operations.
- BLC had positive earnings in 4 of the past 5 years.
- In the past 5 years BLC always reported a positive cash flow from operatings.
1.2 Ratios
- BLC has a worse Return On Assets (0.08%) than 75.00% of its industry peers.
- Looking at the Return On Equity, with a value of 0.74%, BLC is doing worse than 65.63% of the companies in the same industry.
- BLC has a Return On Invested Capital of 6.43%. This is in the better half of the industry: BLC outperforms 62.50% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BLC is in line with the industry average of 7.02%.
- The 3 year average ROIC (6.14%) for BLC is below the current ROIC(6.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROIC | 6.43% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
1.3 Margins
- BLC has a Profit Margin of 0.11%. This is in the lower half of the industry: BLC underperforms 75.00% of its industry peers.
- In the last couple of years the Profit Margin of BLC has declined.
- The Operating Margin of BLC (8.21%) is better than 75.00% of its industry peers.
- BLC's Operating Margin has been stable in the last couple of years.
- The Gross Margin of BLC (67.80%) is better than 78.13% of its industry peers.
- In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.21% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% |
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BLC is creating some value.
- BLC has about the same amout of shares outstanding than it did 1 year ago.
- Compared to 5 years ago, BLC has about the same amount of shares outstanding.
- The debt/assets ratio for BLC has been reduced compared to a year ago.
2.2 Solvency
- BLC has an Altman-Z score of 1.40. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
- BLC's Altman-Z score of 1.40 is on the low side compared to the rest of the industry. BLC is outperformed by 68.75% of its industry peers.
- The Debt to FCF ratio of BLC is 12.90, which is on the high side as it means it would take BLC, 12.90 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of BLC (12.90) is worse than 62.50% of its industry peers.
- BLC has a Debt/Equity ratio of 5.29. This is a high value indicating a heavy dependency on external financing.
- Looking at the Debt to Equity ratio, with a value of 5.29, BLC is doing worse than 84.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Altman-Z | 1.4 |
ROIC/WACC1.28
WACC5.04%
2.3 Liquidity
- BLC has a Current Ratio of 1.38. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.38, BLC is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
- A Quick Ratio of 1.18 indicates that BLC should not have too much problems paying its short term obligations.
- The Quick ratio of BLC (1.18) is better than 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
- BLC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 158.33%, which is quite impressive.
- The earnings per share for BLC have been decreasing by -46.37% on average. This is quite bad
- Looking at the last year, BLC shows a small growth in Revenue. The Revenue has grown by 6.35% in the last year.
- Measured over the past years, BLC shows a small growth in Revenue. The Revenue has been growing by 5.12% on average per year.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
- The Earnings Per Share is expected to grow by 6.18% on average over the next years.
- BLC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.69% yearly.
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 360.00, which means the current valuation is very expensive for BLC.
- Based on the Price/Earnings ratio, BLC is valued a bit more expensive than the industry average as 78.13% of the companies are valued more cheaply.
- BLC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.30.
- With a Price/Forward Earnings ratio of 10.08, the valuation of BLC can be described as very reasonable.
- Based on the Price/Forward Earnings ratio, BLC is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
- BLC is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.04, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 360 | ||
| Fwd PE | 10.08 |
4.2 Price Multiples
- BLC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BLC is cheaper than 90.63% of the companies in the same industry.
- BLC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BLC is cheaper than 81.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.83 | ||
| EV/EBITDA | 5.65 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)18.96
PEG (5Y)N/A
EPS Next 2Y0.72%
EPS Next 3Y6.18%
5. Dividend
5.1 Amount
- BLC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:BLC (1/14/2026, 5:28:56 PM)
25.2
+0.1 (+0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-13 2025-11-13
Earnings (Next)02-12 2026-02-12
Inst Owners11.61%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap185.72M
Revenue(TTM)491.18M
Net Income(TTM)533.00K
Analysts83.33
Price Target36.72 (45.71%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP106.75%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 360 | ||
| Fwd PE | 10.08 | ||
| P/S | 0.38 | ||
| P/FCF | 5.83 | ||
| P/OCF | 2.02 | ||
| P/B | 2.57 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.65 |
EPS(TTM)0.07
EY0.28%
EPS(NY)2.5
Fwd EY9.92%
FCF(TTM)4.32
FCFY17.16%
OCF(TTM)12.48
OCFY49.51%
SpS66.65
BVpS9.79
TBVpS-16.26
PEG (NY)18.96
PEG (5Y)N/A
Graham Number3.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROCE | 8.75% | ||
| ROIC | 6.43% | ||
| ROICexc | 6.81% | ||
| ROICexgc | 12.17% | ||
| OM | 8.21% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% | ||
| FCFM | 6.49% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score8
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Debt/EBITDA | 3.78 | ||
| Cap/Depr | 99.07% | ||
| Cap/Sales | 12.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.09% | ||
| Profit Quality | 5980.3% | ||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z | 1.4 |
F-Score8
WACC5.04%
ROIC/WACC1.28
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
EBIT growth 1Y18.78%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year137.78%
EBIT Next 3Y39.06%
EBIT Next 5YN/A
FCF growth 1Y1.48%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y13.72%
OCF growth 3Y17.38%
OCF growth 5Y14.21%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a valuation rating of 5 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.
What is the expected EPS growth for BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The Earnings per Share (EPS) of BASTIDE LE CONFORT MEDICAL (BLC.PA) is expected to grow by 18.99% in the next year.
Can you provide the dividend sustainability for BLC stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 106.75%.